XTX Topco Ltd Cuts Holdings in Encompass Health Co. (NYSE:EHC)

XTX Topco Ltd lowered its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 68.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,006 shares of the company's stock after selling 13,187 shares during the quarter. XTX Topco Ltd's holdings in Encompass Health were worth $555,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. raised its position in Encompass Health by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock valued at $960,817,000 after purchasing an additional 138,196 shares in the last quarter. Invesco Ltd. grew its holdings in Encompass Health by 3.3% during the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock worth $511,273,000 after acquiring an additional 176,135 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Encompass Health by 6.0% during the 4th quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock worth $191,799,000 after purchasing an additional 117,617 shares during the last quarter. FMR LLC boosted its position in shares of Encompass Health by 0.8% during the 4th quarter. FMR LLC now owns 1,973,846 shares of the company's stock worth $182,285,000 after acquiring an additional 15,831 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Encompass Health by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock valued at $155,176,000 after buying an additional 6,164 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now owns 69,164 shares of the company's stock, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.10% of the company's stock.

Encompass Health Price Performance

EHC traded up $0.63 on Thursday, hitting $101.35. 1,434,434 shares of the company were exchanged, compared to its average volume of 675,637. The business's fifty day moving average is $99.85 and its 200 day moving average is $98.32. Encompass Health Co. has a fifty-two week low of $81.45 and a fifty-two week high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The firm has a market capitalization of $10.21 billion, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, sell-side analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, April 1st. Encompass Health's payout ratio is currently 15.25%.

Analyst Ratings Changes

Several brokerages have issued reports on EHC. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Barclays raised their target price on shares of Encompass Health from $116.00 to $118.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. KeyCorp upped their price target on shares of Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. StockNews.com downgraded shares of Encompass Health from a "buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.